Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry studyResearch in context

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry studyResearch in context

Summary: Background: Clinical guidelines advise osimertinib as preferred first line treatment for advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with deletions in exon 19 (del19) or exon 21 L858R mutation. However, for first-line osimertinib the real wor...

Full description

Bibliographic Details
Main Authors: Rolof G.P. Gijtenbeek, Ronald A.M. Damhuis, Anthonie J. van der Wekken, Lizza E.L. Hendriks, Harry J.M. Groen, Wouter H. van Geffen
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:The Lancet Regional Health. Europe
Subjects:
Non-small cell lung cancer
Epidermal growth factor receptor
Tyrosine kinase inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S2666776223000108

Internet

http://www.sciencedirect.com/science/article/pii/S2666776223000108

Similar Items